Fig. 5: Anti-tumour activity. | Nature Communications

Fig. 5: Anti-tumour activity.

From: Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial

Fig. 5

a Percentage change in CA125 circulating tumour marker for evaluable patients (n = 17; vertical dotted line indicates initiation of dosing; red line indicates a patient with marked CA125 reduction and tumour volume reduction; * and † = tumour marker progression >200%). b Marked but short-lived CA125 reduction following MOv18 IgE dosing in a patient with progression prior to treatment. CA125 relapse coincided with change from weekly to alternate-weekly dosing after 6 weeks. c Pelvic CT images for this patient at baseline and week 6 of treatment showing reduction of peritoneal tumour deposit (red oval). Source data are provided as a Source Data file.

Back to article page